On Monday, June 8, the next meeting of the Transparency Council.
AOTMiT: What will the Transparency Council address on June 8?
Published June 3, 2026 06:42
Źródło: AOTMiT
The agenda includes:
1 Prepare a position paper on the evaluation of the drug Amvuttra (vutrisiran) under drug program B.162. "Treatment of patients with cardiomyopathy (ICD-10: E85, I42.1)".
2 Prepare a position paper on the evaluation of the drug Tezspire (tezepelumabum) under drug program B.156. "Treatment of patients with rhinosinusitis with nasal polyps (ICD-10: J32, J33)".
3 Prepare a position paper on the evaluation of the drug Imfinzi (durvalumabum) under the drug program B.141.FM "Treatment of patients with urothelial carcinoma (ICD-10: C61, C65, C66, C67, C68)".
4. Preparation of a position paper on the examination of the appropriateness of issuing reimbursement approvals for the medicinal products Hydroxocobalamine Acetate Sterop, Megamilbedoce; Hydrocobamine; Vitamin B12 Depot, 1 mg/2 ml; Vitamin B12 Depot, 1 mg/ml for the indications: Methylmalonic aciduria, cobalamin metabolism disorders, cobalamin C deficiency, methylenetetrahydrofolate reductase deficiency (MTHFR deficiency), neuropathy of small nerve fibers (caused by chronic vitamin B12 deficiency).
Source: AOTMiT
